420 related articles for article (PubMed ID: 21540856)
1. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease.
Dominguez-Villar M; Baecher-Allan CM; Hafler DA
Nat Med; 2011 Jun; 17(6):673-5. PubMed ID: 21540856
[TBL] [Abstract][Full Text] [Related]
2. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients.
Frisullo G; Nociti V; Iorio R; Patanella AK; Caggiula M; Marti A; Sancricca C; Angelucci F; Mirabella M; Tonali PA; Batocchi AP
Immunology; 2009 Jul; 127(3):418-28. PubMed ID: 19016907
[TBL] [Abstract][Full Text] [Related]
4. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
[TBL] [Abstract][Full Text] [Related]
5. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Axtell RC; de Jong BA; Boniface K; van der Voort LF; Bhat R; De Sarno P; Naves R; Han M; Zhong F; Castellanos JG; Mair R; Christakos A; Kolkowitz I; Katz L; Killestein J; Polman CH; de Waal Malefyt R; Steinman L; Raman C
Nat Med; 2010 Apr; 16(4):406-12. PubMed ID: 20348925
[TBL] [Abstract][Full Text] [Related]
6. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-12 converts Foxp3+ regulatory T cells to interferon-γ-producing Foxp3+ T cells that inhibit colitis.
Feng T; Cao AT; Weaver CT; Elson CO; Cong Y
Gastroenterology; 2011 Jun; 140(7):2031-43. PubMed ID: 21419767
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a.
Ebrahimimonfared M; Ganji A; Zahedi S; Nourbakhsh P; Ghasami K; Mosayebi G
CNS Neurol Disord Drug Targets; 2018; 17(2):113-118. PubMed ID: 29589548
[TBL] [Abstract][Full Text] [Related]
9. The T-cell pool is anergized in patients with multiple sclerosis in remission.
Fransson ME; Liljenfeldt LS; Fagius J; Tötterman TH; Loskog AS
Immunology; 2009 Jan; 126(1):92-101. PubMed ID: 18624727
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-2 treatment impairs the expansion of T(reg) cell population during acute malaria and enhances the Th1 cell response at the chronic disease.
Zago CA; Bortoluci KR; Sardinha LR; Pretel FD; Castillo-Méndez SI; Freitas do Rosário AP; Hiyane MI; Muxel SM; Rodriguez-Málaga SM; Abrahamsohn IA; Álvarez JM; D'Império Lima MR
PLoS One; 2012; 7(1):e29894. PubMed ID: 22272258
[TBL] [Abstract][Full Text] [Related]
12. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
13. Serum Th1/Th2 and macrophage lineage cytokines in leprosy; correlation with circulating CD4(+) CD25(high) FoxP3(+) T-regs cells.
Abdallah M; Attia EA; Saad AA; El-Khateeb EA; Lotfi RA; Abdallah M; El-Shennawy D
Exp Dermatol; 2014 Oct; 23(10):742-7. PubMed ID: 25109693
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-7 matures suppressive CD127(+) forkhead box P3 (FoxP3)(+) T cells into CD127(-) CD25(high) FoxP3(+) regulatory T cells.
Di Caro V; D'Anneo A; Phillips B; Engman C; Harnaha J; Lakomy R; Styche A; Trucco M; Giannoukakis N
Clin Exp Immunol; 2011 Jul; 165(1):60-76. PubMed ID: 21413939
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL) -17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis.
Dutzan N; Gamonal J; Silva A; Sanz M; Vernal R
J Clin Periodontol; 2009 May; 36(5):396-403. PubMed ID: 19419438
[TBL] [Abstract][Full Text] [Related]
16. T-bet regulates differentiation of forkhead box protein 3+ regulatory T cells in programmed cell death-1-deficient mice.
Tahara M; Kondo Y; Yokosawa M; Tsuboi H; Takahashi S; Shibayama S; Matsumoto I; Sumida T
Clin Exp Immunol; 2015 Feb; 179(2):197-209. PubMed ID: 25219397
[TBL] [Abstract][Full Text] [Related]
17. Identification of a human Th1-like IFNγ-secreting Treg subtype deriving from effector T cells.
Venigalla RK; Guttikonda PJ; Eckstein V; Ho AD; Sertel S; Lorenz HM; Tretter T
J Autoimmun; 2012 Dec; 39(4):377-87. PubMed ID: 22824211
[TBL] [Abstract][Full Text] [Related]
18. CD4+CD25+Foxp3+ T regulatory cells, Th1 (CCR5, IL-2, IFN-γ) and Th2 (CCR4, IL-4, Il-13) type chemokine receptors and intracellular cytokines in children with common variable immunodeficiency.
Kutukculer N; Azarsiz E; Aksu G; Karaca NE
Int J Immunopathol Pharmacol; 2016 Jun; 29(2):241-51. PubMed ID: 26684629
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.
Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O
Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108
[TBL] [Abstract][Full Text] [Related]
20. Determination of a CD4
Jafarinia M; Mehdipour F; Hosseini SV; Ghahramani L; Hosseinzadeh M; Ghaderi A
Tumour Biol; 2016 Nov; 37(11):14659-14666. PubMed ID: 27619682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
